MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Work
Year: 2019
Type: article
Abstract: At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with a tolerable s... more
Source: npj Breast Cancer
Institutions Royal Marsden NHS Foundation Trust, Universidad Complutense de Madrid, Hospital General Universitario Gregorio Marañón, Hospital of Prato, Seoul National University Hospital +8 more
Cites: 30
Cited by: 526
Related to: 10
FWCI: 49.69
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $3,170